Activin A, a member of the transforming growth factor beta (TGF-b) superfamily, aects keratinocyte proliferation and dierentiation in vitro and in vivo. However, little is known about the mechanisms of activin action in keratinocytes, and its target genes have not been identi®ed. In this study, we demonstrate that activin A and TGF-b1 directly induce the expression and activity of Mad1, an antagonist of the c-Myc transcription factor, in the human HaCaT keratinocyte cell line. Expression and activity of Mad1 was strongly induced by both factors in keratinocytes, although the intensity of induction was dierent for activin A and TGF-b1. To determine a possible role of activin and TGF-b in the regulation of mad1 expression in vivo, we analysed its expression during cutaneous wound repair when high levels of these factors are present. Expression of mad1 mRNA and protein, but not of other mad genes, increased signi®cantly after skin injury, particularly in polymorphonuclear leukocytes and in suprabasal keratinocytes of the hyperproliferative epithelium. Elevated levels of mad1 mRNA were also detected in the hyperthickened epidermis of psoriatic patients. Since Mad1 regulates proliferation and/or dierentiation of various cell types, our results suggest that this transcription factor mediates at least in the part the anti-mitotic and/or dierentiation-inducing activities of TGF-b and activin in keratinocytes. Oncogene (2001) 20, 7494 ± 7504.
Introduction
Polypeptides of the transforming growth factor b (TGF-b) family are known to be key players in embryonic development and in tissue repair. In mammals, this family includes for example three types of TGF-b (TGF-b1, b2, and b3), various bone morphogenetic proteins (BMPs), mullerian inhibiting substance, inhibins and activins (for review see MassagueÂ , 1990) . A series of studies have provided insight into the important function of TGF-bs in skin morphogenesis and wound repair (for review see Roberts and Sporn, 1996) . However, an in vivo function of activin in these processes has only recently been demonstrated. The ®rst evidence for a possible role of activin in the skin resulted from the phenotypes of knockout mice. Besides various defects which caused death within the ®rst 24 h after birth, activin bA knockout mice lacked whiskers and whisker follicles were abnormal (Matzuk et al., 1995a) . Mice de®cient in follistatin, the antagonist of activin, showed disturbed whisker development and hyperkeratotic skin (Matzuk et al., 1995b) . Finally, transgenic mice that overexpress the activin bA chain in the basal layer of the epidermis revealed ®brosis in the dermis and a hyperthickened epidermis which was characterized by abnormal keratinocyte dierentiation (Munz et al., 1999) . A role of activin in the regulation of keratinocyte proliferation and dierentiation was further supported by in vitro studies demonstrating a weak inhibitory eect of activin on keratinocyte proliferation and induction of keratinocyte dierentiation by this factor (Shimizu et al., 1998; Seishima et al., 1999) . Besides this obvious function of activin in normal skin, recent studies from our laboratory demonstrated a novel and important role of activin in wound repair. Thus activin mRNA levels increased signi®cantly after skin injury (HuÈ bner et al., 1996) . This increase is likely to be of functional importance, since the wound healing process was strikingly enhanced in the transgenic mice that overexpress activin A in the epidermis (Munz et al., 1999) . These ®ndings indicated an important and unique role of activin in normal and wounded skin which diers from the known eects of TGF-bs in this tissue. However, the mechanisms which underlie the eects of activin on keratinocytes and other cell types in the skin have yet to be elucidated.
To address this question, we searched for genes which are regulated by activin A and/or TGF-b1 in cultured keratinocytes. Since activin aects keratinocyte dierentiation (Seishima et al., 1999) , we tested the eect of activin on the expression of genes that have been suggested to regulate this process. One of them codes for Mad1, a basic region/helix ± loop ± helix/ leucine zipper transcriptional regulator which can dimerize with the Max protein (Ayer et al., 1993) .
Mad1/Max heterodimers antagonize the transcriptional activation exerted by a complex between Max and the Myc proto-oncoprotein (Grandori et al., 2000) . Mad1 is a member of a family of transcriptional regulators that also includes Mxi1/Mad2, Mad3, and Mad4 (Zervos et al., 1993; Hurlin et al., 1995a) .
Expression of Mad1 appears closely linked to terminal dierentiation of many dierent cell types (reviewed by Grandori et al., 2000) . Most importantly, a series of in vitro and in vivo expression studies and the inhibition of colony formation in a mouse keratinocyte cell line by Mad1 overexpression (VaÈ strik et al., 1995; Hurlin et al., 1995a,b, Gandarillas and Watt, 1995; Lymboussaki et al., 1996) suggest that Mad1 is involved in the cessation of cell proliferation associated with keratinocyte dierentiation. Here we show a striking increase in the expression of mad1 mRNA and protein upon addition of activin A or TGF-b1 to keratinocytes, indicating that Mad1 is involved in the regulation of keratinocyte proliferation and/or dierentiation by these factors. Furthermore, we provide evidence for a role of Mad1 in the regulation of these processes in normal, wounded and psoriatic skin.
Results

Regulation of mad1 mRNA and protein expression in HaCaT cells by activin A and TGF-b1
Since activin has been shown to play a role in the regulation of keratinocyte proliferation and dierentiation, we determined the eect of activin A and its homologue TGF-b1 on the expression of the transcriptional regulator Mad1. The latter has been suggested to regulate dierentiation of various cell types. For this purpose we stimulated quiescent human immortalized keratinocytes (HaCaT cells) with activin A or TGF-b1 and isolated the RNA at dierent time points. As shown by RNase protection assay (Figure 1a ), mad1 mRNA levels were ®vefold up-regulated 90 min after addition of activin A to the culture medium. An even stronger mRNA induction (sevenfold) was seen upon TGFb-1-treatment ( Figure 1a) . Pretreatment of the cells with the protein synthesis inhibitor cycloheximide strongly increased the basal and activin A-/TGF-bmediated expression of mad1, demonstrating that induction of this gene is a direct response to the action of these growth and dierentiation factors (Figure 1b) .
In an analogous experiment, we prepared total cell lysates, nuclear lysates and cytosolic fractions from activin A-and TGF-b1-treated cells and determined the level of Mad1 in the lysates by Western blot analysis. As shown in Figure 2a , a fourfold upregulation of the Mad1 protein (35 kDa) occurred after activin A treatment and a sevenfold increase was seen in the presence of TGF-b1. Maximal induction was observed 3 h after growth factor addition. After 5 ± 8 h Mad1 had returned to its basal level. The identity of the detected protein with Mad1 was con®rmed by Western blot analysis of COS-1 cells that had been transiently transfected with a mad1 expression vector. The transfected protein was detected by the Mad1 antibody and corresponded in size to the one that reacted with the antibody in HaCaT cells (Figure 2a) . No signal was observed when the blot was probed with the Mad1 antibody that had been pretreated with the immunization peptide, demonstrating the speci®city of the Mad1 signal (data not shown). Since Mad1 can only inhibit c-Myc function when present in the nucleus, we determined the intracellular localization of the protein. As shown in Figure 2b , Mad1 was predominantly found in the nucleus. By contrast, little Mad1 was detected in the cytosolic Figure 1 Activin A and TGF-b1 directly induce mad1 mRNA expression in HaCaT keratinocytes. (a) HaCaT keratinocytes were rendered quiescent by serum starvation and subsequently treated with 18 ng/ml activin A or 1 ng/ml TGF-b1. Total cellular RNA was isolated from these cells at dierent time points after addition of activin A or TGF-b1 as indicated. (b) To analyse if the induction of mad1 by activin A and TGF-b1 is a direct eect, HaCaT keratinocytes were rendered quiescent by serum starvation and treated with 10 mg/ml cycloheximide dissolved in DMSO. After 1 h 18 ng/ml activin A or 1 ng/ml TGF-b1 were added. Control cells were treated with the solvent DMSO. Total cellular RNA was isolated from these cells at dierent time points after activin A or TGF-b1 addition as indicated. Samples of 20 mg RNA were analysed by RNase protection assay for the expression of mad1 mRNA. One mg of each RNA sample was loaded on a 1% agarose gel and stained with ethidium bromide (shown below the RNase protection assay). Fifty mg tRNA was used as a negative control. One thousand c.p.m. of the hybridization probes were loaded in the lanes labelled`probe' and used as a size marker. Note the increased basal and activin A/TGF-b1 induced expression levels of mad1 in the cycloheximide-treated cells fraction. The enrichment of Mad1 in the nucleus after activin/TGF-b1 treatment, suggests that these growth and dierentiation factors increase the amount of functionally active Mad1 in the cell.
Regulation of Mad1 activity by activin A and TGF-b1 in HaCaT keratinocytes
To further determine whether the increase in mad1 expression correlates with increased Mad1 DNAbinding activity, we next studied the Mad1 DNAbinding activity after activin A and TGF-b1 treatment. For this purpose we used a solid-phase DNA-binding assay as described by Larsson et al. (1997) . The latter is a combination of immunoprecipitation and DNAbinding assay. Within 3 h after growth factor addition we observed an increased binding of Mad1 immunocomplexes to the labelled CMD-oligonucleotide which contains an optimal Myc/Max-binding site (Figure 3 ). Activin A treatment enhanced the Mad1 binding activity 1.7-fold, TGF-b1 treatment caused a 2.3-fold increase. Using the labelled CMM-oligonucleotide (which contains the mutated Myc/Max-binding site) no Mad1 binding could be detected. The Mad1 binding to the CMD-oligonucleotide was completely competed with a 100-fold molar excess of unlabelled CMD, but not by addition of an unspeci®c oligonucleotide (Figure 3) .
Induction of activin A and TGF-b1 is unique to mad1
In contrast to mad1, expression of mad2 and mad4 was not regulated by activin and TGF-b1 under the same conditions (data not shown). Consistent with published data obtained with a mouse keratinocyte cell line (Coey et al., 1988; Pietenpol et al., 1990) , expression of c-myc was strongly downregulated by TGF-b1 in HaCaT cells (Figure 4 ). In addition, activin A treatment of these cells reduced the levels of c-myc mRNA. The downregulation by activin was weaker HaCaT keratinocytes were rendered quiescent by serum starvation and subsequently treated with 18 ng/ml activin A or 1 ng/ml TGF-b1. (a,b) Total cell lysates (a), nuclear lysates (b) or cytosolic fractions (b) were prepared at dierent time points after addition of activin A or TGF-b1. 120 mg (whole cell lysate), 80 mg (cytosolic fraction) or 40 mg (nuclear lysate) protein was analysed by Western blotting for the presence of Mad1. Bands were visualized with the ECL detection system. Total lysate from COS-1 cells that had been transfected with a mad1 expression vector was used as a positive control (a, right panel) Figure 3 Activin A and TGF-b1 induce the Mad1 DNA-binding activity. HaCaT keratinocytes were rendered quiescent by serum starvation and subsequently treated with 18 ng/ml activin A or 1 ng/ml TGF-b1. F-buer lysates were prepared 3 h after the induction. Total protein lysates from quiescent (control) and activin A-or TGF-b1-treated cells were analysed by a solid-phase DNA-binding assay. DNA-binding was analysed with the 32 Plabelled CMD-oligonucleotide (which contains an optimal Myc/ Max-binding site) or with the 32 P-labelled CMM-oligonucleotide (which has a mutated Myc/Max-binding site). The speci®city of the binding was determined by competition with a 100-fold excess of unlabelled CMD-or non-speci®c oligonucleotide, respectively. The DNA-binding activity is indicated as per cent of control. Each bar indicates the mean+s.e.m. for duplicate (activin) or triplicate (TGF-b1) determinations compared to TGF-b1 (Figure 4 ), but the suppression was more long-lasting. In addition to Myc and Mad1, the Max transcription factor has also been shown to dimerize with the Mnt/Rox protein (Hurlin et al., 1997; Meroni et al., 1997) . Expression of the latter, however, was not aected by either TGF-b1 or activin A (data not shown). Therefore, Mad1 appears to be the major c-Myc antagonist in activin A-/TGF-b1-treated HaCaT cells.
Mad1 expression is regulated in a biphasic manner during cutaneous wound repair
To determine a possible regulation of mad1 expression by activin or TGF-b in vivo, we analysed the expression of this transcription factor during the healing process of full-thickness excisional mouse wounds where high levels of these factors are expressed (HuÈ bner et al., 1996; Frank et al., 1996) . The time points that we chose are characteristic for the dierent phases of wound repair: The early in¯ammatory phase, which is characterized by in¯ux and activation of neutrophils and macrophages (days 1 ± 3) the phase of new tissue formation (days 3 ± 7), and the phase of tissue remodelling (starting around day 7). As shown in Figure 5a , mad1 mRNA was weakly expressed in normal skin. Consistent with results from a previous study (Lymboussaki et al., 1996) , mad1 mRNA levels increased after skin injury. Interestingly, we observed a biphasic regulation with a ®rst maximum at day 1 after wounding and a second maximum after 5 days. This biphasic regulation was con®rmed for the protein by Western blot analysis ( Figure 5b ). These results were reproduced with a dierent set of RNAs or protein lysates from an independent wound healing experiment. Taken together, our ®ndings reveal a complex regulation of mad1 expression during in vivo wound repair.
Mad1 is expressed in polymorphonuclear leukocytes and in suprabasal keratinocytes of the hyperproliferative epithelium
To localize mad1 mRNA we performed in situ hybridization with sections from wounded skin (days 1 and 5 after injury). As shown in Figure 6a ± d, mad1 mRNA was predominantly detected within the clot (Cl) that had formed 1 day after injury. At higher magni®cation the mad1-expressing cells were identi®ed as polymorphonuclear leukocytes as re- Figure 4 Activin A and TGF-b1 suppress c-myc mRNA expression in HaCaT keratinocytes. (a) HaCaT keratinocytes were rendered quiescent by serum starvation and subsequently treated with 18 ng/ml activin A or 1 ng/ml TGF-b1. Total cellular RNA was isolated from these cells at dierent time points after addition of activin A or TGF-b1 as indicated. Samples of 20 mg RNA were analysed by RNase protection assay for the expression of c-myc mRNA. One mg of each RNA sample was loaded on a 1% agarose gel and stained with ethidium bromide (not shown). Fifty mg tRNA was used as a negative control. One thousand c.p.m. of the hybridization probe were loaded in the lane labelled probe' and used as a size marker. The intensity of the bands was analysed by laser scanning densitometry of the autoradiograms and is shown schematically in the RNase Protection Assay. (b) The intensity seen in non-treated keratinocytes was set at 100% Figure 5 Increased expression of mad1 mRNA and protein after skin injury. (a) RNA was isolated from full-thickness excisional wounds of BALB/c mice at dierent time points after injury. Twenty mg total cellular RNA from non-wounded (skin) and wounded skin (wound) were analysed by RNase protection assay for the expression of mad1 mRNA. Fifty mg tRNA was used as a negative control. One thousand c.p.m. of the hybridization probe was loaded in the lane labelled`probe' and used as a size marker. One mg of each RNA sample was loaded on a 1% agarose gel and stained with ethidium bromide. A picture of the RNA gel is shown below the RNase protection assays. (b) One hundred and twenty mg total protein from normal and wounded skin was analysed by Western blotting for the expression of Mad1
vealed by the characteristic shape of their nuclei (Figure 6d ).
Five days after wounding mad1 was expressed in keratinocytes of the upper suprabasal layers of the Figure 6 Mad1 mRNA is expressed in polymorphonuclear leukocytes in the clot and in dierentiated keratinocytes of the hyperproliferative epithelium of full-thickness excisional mouse wounds. Paraformaldehyde-®xed frozen sections were taken from the middle of 1d (a ± e) and 5d (f ± i) wounds and analysed by in situ hybridization for the presence of mad1 mRNA using a a-35 Slabelled mouse mad1 antisense RNA. Hybridization with the corresponding sense RNA was used as a negative control (e and i). Signals appear as white dots in the dark ®eld surveys (b,c,e,f,i) and as black dots in the bright ®eld surveys (a,d,g,h) . Note the presence of mad1 mRNA in polymorphonuclear leukocytes of 1d wounds and in suprabasal keratinocytes of the hyperproliferative epithelium of 5d wounds. The area which is shown at high magni®cation in (d) is marked with a rectangle in (a). The border between the hyperproliferative epithelium and the granulation tissue is marked with a dotted line in (g) and (h). hyperproliferative epithelium (HE) which have lost their proliferative capacity. By contrast, only weak signals were observed in basal, non-dierentiated keratinocytes and in the underlying granulation tissue (Figure 6f ± h) . Furthermore, mad1 mRNA was not detectable in the normal epidermis at a distance from the wound (data not shown). No speci®c signals were obtained with the sense riboprobe (Figure 6e and i) . Thus mad1 expression is predominantly associated with dierentiated cells in the wound area. These cells have also been shown to express activin and the three dierent types of TGF-b (HuÈ bner et al., 1996; Frank et al., 1996) , suggesting that these growth and dierentiation factors might be responsible for the induction of mad1 expression in dierentiated keratinocytes.
Expression of the other mad-family members, mxi1/ mad2, mad3 and mad4 is differentially regulated compared to mad1 during cutaneous wound repair
To determine a possible role of other Mad proteins in the healing process, we investigated the regulation of mxi1/mad2, mad3 and mad4 mRNA expression after skin injury. As shown in Figure 7 , mxi1/mad2 and mad4 were expressed at fairly high levels in both normal and wounded skin, but their expression levels did not change after injury. Mad3 mRNA, which was hardly detectable in normal skin, was weakly upregulated 5 ± 7 days after skin injury. In addition, the mRNA encoding mnt/rox was hardly detectable in normal and wounded skin. C-myc was expressed at low levels in normal skin, but was transiently up-regulated within 6 ± 24 h after wounding (Figure 7 and data not shown). The maximum occurred after 6 h.
Mad1 function has recently been shown to be antagonized by the leucine zipper protein Mmip-1 (Gupta et al., 1998) and by the unrelated RING ®nger-containing protein Mmip-2 (Yin et al., 1999) . Mmip-1 mRNA was expressed at moderate levels in normal and wounded skin, but its expression was not regulated by injury (Figure 7) . Expression of mmip-2 mRNA could neither be detected in normal nor in wounded skin (data not shown). These results were reproduced with a dierent set of RNAs from an independent wound healing experiment.
Mad1 expression is upregulated in psoriatic skin
The strong expression of mad1 in the suprabasal cells of the hyperproliferative wound epithelium tempted us to speculate about a role of Mad1 in hyperproliferative skin disease. Therefore, we determined its expression in the skin of patients suering from the in¯ammatory skin disease psoriasis. The latter is characterized by hyperproliferation of the keratinocytes and abnormalities in their dierentiation process. As shown in Figure  8a , mad1 mRNA levels were indeed fourfold higher in the aected skin of psoriatic patients (n=8, four patients shown) compared to healthy control patients (n=5, two patients shown). This result was con®rmed by in situ hybridization. Thus, mad1 mRNA was hardly detectable in normal human skin ( Figure  8d,e) , but strong signals were found in the upper suprabasal layers of the hyperthickened epidermis of psoriatic patients (Figure 8b,c) . No signal was obtained with the sense probe (data not shown).
Discussion
Recent studies from us and from others have revealed a novel role of the TGF-b superfamily member activin in the regulation of keratinocyte proliferation and dierentiation (Shimizu et al., 1998; Seishima et al., 1999; Munz et al., 1999) . Interestingly, the eects of activin on keratinocytes seem to dier from those of Figure 7 Expression of mxi1/mad2, mad3, mad4, mnt/rox, c-myc and mmip1 mRNAs in normal and wounded skin. RNA was isolated from full-thickness excisional wounds of BALB/c mice at dierent time points after injury. Twenty mg total cellular RNA from non-wounded (skin) and wounded skin (wound) were analysed by RNase protection assay for the expression of mxi1/ mad2, mad3, mad4, rox/mnt, c-myc and mmip1 mRNAs as indicated. Fifty mg tRNA was used as a negative control. One thousand c.p.m. of the hybridization probes were loaded in the lanes labelled`probe' and used as size markers. One mg of each RNA sample was loaded on a 1% agarose gel and stained with ethidium bromide. A picture of the RNA gel is shown below the RNase protection assays. The same set of RNAs was used for the RNase protection assays shown here and in Figure 5 TGF-b, since the latter caused a much stronger inhibition of keratinocyte proliferation in vitro compared to activin (Shimizu et al., 1998; Seishima et al., 1999) . In vivo, the dierences were even more striking, since targeted expression of TGF-b1 in the epidermis of transgenic mice caused severe inhibition of keratinocyte proliferation (Sellheyer et al., 1993 , Wang et al., 1999 . By contrast, activin overexpression in the epidermis even resulted in keratinocyte hyperproliferation and thickening of the epidermis (Munz et al., 1999) . This eect is probably indirect, since activin is a weak inhibitor of keratinocyte proliferation in vitro (Shimizu et al., 1998) . Thus, a dermally derived mitogen that is induced by the activin released from keratinocytes might be responsible for the stimulation of keratinocyte proliferation. Interestingly, activin Figure 8 Increased expression of mad1 mRNA and protein in psoriatic skin. (a) Ten mg RNA isolated from skin biopsies of normal (ctr) and psoriatic skin (patient; P) was analysed by RNase protection assay for the presence of mad1 mRNA. Fifty mg tRNA were used as a negative control. One thousand c.p.m. of the hybridization probe was loaded in the lane labelled`probe' and used as a size marker. One mg of each RNA sample was loaded on a 1% agarose gel and stained with ethidium bromide. A picture of the RNA gel is shown below the RNase protection assays. (b ± e) In situ hybridization showing mad1 expression in the suprabasal layers of psoriatic skin. Paraformaldehyde-®xed frozen sections were taken from normal (d,e) and psoriatic (b,c) human skin and analysed by in situ hybridization for the presence of mad1 mRNA using a a-35 S-labelled human mad1 antisense RNA. Signals appear as white dots in the dark ®eld surveys (c,e) and as black dots in the bright ®eld surveys (b,d). Magni®cations: 2006. E: Epidermis, D: Dermis, HE: Hyperproliferative epithelium overexpression in the skin was shown to aect keratinocyte dierentiation (Munz et al., 1999) , whereas this was not the case with TGF-b1 (Sellheyer et al., 1993; Wang et al., 1999) . Therefore, it seemed likely that the two TGF-b superfamily members regulate the expression of a dierent set of genes. In a search for genes which are regulated by TGF-b and/ or activin we recently identi®ed several genes which are exclusively regulated by TGF-b1, including calpactin I (Munz et al., 1997) and keratin 15 (Werner et al., 2000) . By contrast, genes that are regulated by activin in keratinocytes have as yet not been identi®ed.
In the present study we have identi®ed the gene encoding the Mad1 transcriptional regulator as the ®rst activin target gene in epidermal keratinocytes. Interestingly, the eect was direct, demonstrating that mad1 is a primary response gene in keratinocytes. Mad1 is one of four members of the Mad family that have all been shown to antagonize the function of Myc proteins by recruiting a transcriptional repressor complex that contains histone deacetylase activity (Sommer et al., 1997; Laherty et al., 1997; Alland et al., 1997) . Expression of all Mad proteins correlates in general with growth inhibition and terminal dierentiation of many cell types, including keratinocytes of the epidermis (reviewed by Grandori et al., 2000) . Thus, Mad family members are predominantly expressed in the suprabasal, dierentiated layers of embryonic and adult skin (Hurlin et al., 1995a,b; VaÈ strik et al., 1995; Lymboussaki et al., 1996) . Furthermore, induction of keratinocyte dierentiation in vitro is accompanied by an increase in mad1 and mxi1/mad2 expression (Gandarillas and Watt, 1995) . Finally, transfection of a mouse keratinocyte cell line with mad1 strongly inhibited colony formation of these cells (VaÈ strik et al., 1995) . Therefore, it seems likely that in addition to the suppression of c-myc expression by TGF-b (Pietenpol et al., 1990) , the increased expression of mad1 in response to TGF-b1 and activin is at least partially responsible for the growth inhibitory eect of these factors for keratinocytes. Thereby the stronger induction of mad1 expression by TGF-b1 correlates with the more potent growth inhibitory eect of the latter in comparison to activin. This inhibitory eect of Mad1 on keratinocyte proliferation is likely to be a prerequisite for subsequent dierentiation of these cells. However, mad1 expression is probably not sucient for the induction of the dierentiation process, since the potent mad1 inducer TGF-b has little eect on keratinocyte dierentiation (see above) and since overexpression of mad1 in keratinocytes was obviously not sucient to induce the dierentiation program (described in Grandori et al., 2000 , as unpublished data by P Gallant and RN Eisenman).
To gain insight into a possible role of activin and TGF-b1 in the regulation of mad1 expression in vivo, we analysed its expression during cutaneous wound repair where high levels of these factors are present (Frank et al., 1996; HuÈ bner et al., 1996 ; reviewed by Martin, 1997; O'Kane and Ferguson, 1997) . Consistent with previous data (Lymboussaki et al., 1996) , the mRNA expression of mad1 was upregulated after skin injury. In the present study we show that the increased mRNA also leads to elevated levels of Mad1 protein.
The upregulation was shown to be unique for mad1, since the other mad family members were expressed at equal levels in normal and wounded skin. Most interestingly, we identi®ed two peaks of mad1 expression. The ®rst peak occurred between 12 and 24 h after injury, a period that is characterized by a strong in¯ammatory response. The second peak was found between days 5 and 7 after wounding and coincides with the strongly enhanced formation of new tissue. In situ hybridization revealed that suprabasal, redierentiating keratinocytes of the epidermis are responsible for the second peak (Lymboussaki et al., 1996; this study) .
In addition, polymorphonuclear leukocytes were identi®ed as a novel site of mad1 expression in wounds that explains the early peak in the levels of mad1 mRNA and protein. These cells are attracted to the site of injury and subsequently become activated to ful®l their task of bacterial destruction. After this period they become entrapped within the wound clot or they become senescent and are phagocytosed by macrophages (reviewed by Clark, 1996) . The high levels of Mad1 in these cells indicate a role of this transcription factor in neutrophil activation as supported by results obtained in in vitro dierentiation models (Larsson et al., 1994; Sommer et al., 1998) . Alternatively, Mad1 might inhibit apoptosis of these cells at this stage of the repair process. This hypothesis is supported by the recently demonstrated anti-apoptotic activity of Mad1 in other cells (Gehring et al., 2000) . Most importantly, granulocytic precursor cells of mice lacking the mad1 gene were characterized by decreased survival under cytokine-limiting conditions (Foley et al., 1998) , whereas mad1 overexpression decreased the proliferative capacity of these cells and increased their survival when cytokine levels were reduced (Queva et al., 1999) .
Interestingly, the temporal and spatial expression of mad1 correlates nicely with the expression pattern of TGF-b1 and activin. Thus, TGF-b1 is released in large amounts from degranulating platelets after wounding (Assoian et al., 1983) and might thus be responsible for the early increase in mad1 expression. Furthermore, both activin and TGF-b are highly expressed during the proliferative phase of wound repair, and particularly high levels of the corresponding mRNAs and proteins were detected in the mad1 positive suprabasal keratinocytes of the hyperproliferative wound epithelium at the same stage of repair in the same wound healing model (Frank et al., 1996; HuÈ bner et al., 1996) . Therefore, it seems likely that activin and TGF-b are also involved in the regulation of mad1 expression in vivo. This hypothesis is further supported by preliminary ®ndings from our laboratory that revealed a higher mad1 expression in the skin of mice that overexpress activin in the epidermis.
The strong expression of mad1 in polymorphonuclear leukocytes as well as in suprabasal keratinocytes suggests a possible role of this transcription factor in the pathogenesis of skin diseases that are characterized by in¯ammation and/or epidermal hyperproliferation. This hypothesis is supported by the particularly strong expression of mad1 in the granular layer of chemically-or virally-induced mouse skin carcinomas as well as in human squamous and basal cell carcinomas that retain dierentiation capacity. In these skin tumours the levels of mad1 mRNA increased with the thickness of the dierentiated cell layers (Hurlin et al., 1995b; Lymboussaki et al., 1996) . In this study we demonstrate that mad1 overexpression is not restricted to malignant tumours but is also observed in the skin of patients suering from the benign in¯ammatory skin disease psoriasis that is characterized by epidermal hyperproliferation. Due to the known inhibitory eect of Mad1 on keratinocyte proliferation, it seems possible that the presence of this protein in hyperthickened epidermis of wounds, psoriatic lesions and skin tumours limits the hyperproliferation of keratinocytes under these conditions. Alternatively, Mad1 could also inhibit keratinocyte death by terminal dierentiation, which has been shown to share features with programmed cell death (reviewed by Gandarillas, 2000) . This hypothesis is supported by the potent antiapoptotic eect of Mad1 for many other cell types (Gehring et al., 2000) . The analysis of the wound healing process in mice lacking dierent mad genes (Foley et al., 1998; Schreiber-Agus et al., 1998; Queva et al., 2001) as well as skin carcinogenesis studies in these animals will help to further de®ne the role of Mad1 in keratinocyte proliferation, dierentiation and apoptosis in vivo.
Materials and methods
Cell culture and growth factor treatment of keratinocytes
HaCaT keratinocytes (Boukamp et al., 1988) were grown to con¯uency in Dulbecco's modi®ed Eagle's medium (DMEM) containing 1% Penicillin/Streptomycin and 10% foetal calf serum (FCS). They were rendered quiescent by serum starvation for 24 ± 32 h and subsequently treated with fresh DMEM containing 1 ng/ml TGF-b1 or 18 ng/ml activin A, respectively. These concentrations have been shown to inhibit keratinocyte proliferation, to induce their dierentiation (Seishima et al., 1999) , and to elicit maximal transcriptional responses in HaCaT cells (S Werner, unpublished data) . For inhibition of protein synthesis cells were treated 1 h before the addition of the growth factors with 1 mg/ml cycloheximide dissolved in DMSO. Control cells were incubated with the solvent DMSO. Cells were harvested at dierent time points after addition of activin A/TGF-b1, and used for RNA isolation or preparation of cell lysates. Each experiment was repeated at least twice. DMEM was purchased from Sigma (Deisenhofen, Germany), FCS was from BioConcept Amimed (Allschwil, Switzerland), TGF-b1 was from Roche Biochemicals (Rotkreuz, Switzerland). Activin was kindly provided by Dr Denis Gospodarowicz, Chiron Corporation (Emeryville, CA, USA).
Preparation of whole cell lysates and nuclear lysates
For the preparation of HaCaT cell lysates, 500 ml of lysis buer (1% Triton X-100, 20 mM Tris/HCl pH 8.0, 137 mM NaCl, 10% glycerol, 2 mM EDTA, 1 mM PMSF, 0.15 U/ml Aprotinin, 1% Leupeptin, 1% Pepstatin, 1 mM Na 2 P 2 O 7 and 1 mM Na 3 VO 4 ) was added to each 10 cm petri dish and incubated for 10 min at 48C on a rocker. Subsequently, the cells were scraped o the dish and the lysates were sonicated.
To separate the cytosolic fraction from the nuclei, cells were incubated for 10 min in lysis buer (see above). The supernatant (cytosolic fraction) was removed and the remaining nuclei were scraped o the dish and sonicated.
Transfection of COS-1 cells
COS-1 cells were transiently transfected with a CMV-Mad1 expression construct (Sommer et al., 1998) using the calcium phosphate transfection method (Chen and Okayama, 1987) . Brie¯y, 5610 5 cells in 6 cm petri dishes were transfected with 4 mg of the puri®ed plasmid in a calcium phosphate precipitate. After a 5 h incubation cells were washed with HEPES buer (142 mM NaCl, 10 mM HEPES pH 7.3, 6.7 mM KCl) and cultured in DMEM/10% FCS for 48 h.
RNA isolation and RNase protection assay
Isolation of total cellular RNA was performed as described by Chomczynski and Sacchi (1987) . RNase protection assays were carried out according to Werner et al. (1993) . Autoradiograms were scanned and analysed with the Scion Image software (Scion Corporation, MD, USA).
cDNA templates
For RNase protection assays we generated cDNA templates by RT ± PCR using RNA from mouse wounds or HaCaT keratinocytes. A human mad1 cDNA probe was obtained using 5'-d(GCATCGGCTCCACCGTCTCC)-3' as a 5'-primer and 5'-d(AAGGAGACAGCCGCAGTGCC)-3' as a 3'-primer. The ampli®ed fragment corresponds to nucleotides 581 ± 840 of the published sequence (Ayer et al., 1993; accession number 4505068) . A mouse mad1 cDNA probe was obtained using 5'-d(CATACAGCAAGGACAGAG)-3' as a 5'-primer and 5'-d(AGCTGGTCTATTTGGTGG)-3' as a 3'-primer. The ampli®ed fragment corresponds to nucleotides 153 ± 411 of the published cDNA sequence (VaÈ strik et al., 1995; accession number X83106). A mouse mxi1/mad2 cDNA probe was obtained using 5'-d(AGATGGAGCGGATACGAA)-3' as a 5'-primer and 5'-d(TCCGCCCTGCACTGTTAG)-3' as a 3'-primer. The ampli®ed fragment corresponds to nucleotides 472 ± 735 of the sequence published in the database (accession number: NM_010847), although a few mismatches were detected. A mouse mad3 cDNA probe was obtained using 5'-d(TGCATATCCAGAAGCTGG)-3' as a 5'-primer and 5'-d(GAGCTCTGTTTCAGTCCC)-3' as a 3'-primer. The ampli®ed fragment corresponds to nucleotides 311 ± 558 of the published cDNA sequence (Hurlin et al., 1995a; accession number: NM_016662) . A mouse mad4 cDNA probe was obtained using 5'-d(GCCCGAACAACAGGTCTT)-3' as a 5'-primer and 5'-d(CGCACACGCTCTACACTC)-3' as a 3'-primer. The ampli®ed fragment corresponds to nucleotides 152 ± 425 of the published cDNA sequence (Hurlin et al., 1995a; accession number: NM_010753) . A mouse mnt/rox cDNA probe was obtained using 5'-d(GGCAAGCGCAGCAA-CAAC)-3' as a 5'-primer and 5'-d(GCAGGGGTGG-CAAGTGGT)-3' as a 3'-primer. The ampli®ed fragment corresponds to nucleotides 395 ± 608 of the published cDNA sequence (Meroni et al., 1997; accession number: NM_010813) . A mouse mmip1 cDNA probe was obtained using 5'-d(TGAATCTTCCTGGAGAGG)-3' as a 5'-primer and 5'-d(TCGATGGCTGACTTGATC)-3' as a 3'-primer. The ampli®ed fragment corresponds to nucleotides 308 ± 555 of the published cDNA sequence (Gupta et al., 1998; accession number: Y15128) . A mouse c-myc cDNA probe was obtained using 5'-d(GTGCTCCAGCCCCAGGTCCT)-3' as a 5'-primer and 5'-d(GTTTATGCACCAGAGTTTCG)-3' as a 3'-primer. The ampli®ed fragment corresponds to nucleotides 1629 ± 1928 of the published cDNA sequence (Stanton et al., 1984; accession number: X01023) . A human c-myc cDNA probe was obtained using 5'-d(ATGCACCAGCCCCAGGTCCT)-3' as a 5'-primer and 5'-d(CCTTACGCACAAGAGTTCCG)-3' as a 3'-primer. The ampli®ed fragment corresponds to nucleotides 1581 ± 1961 of the published cDNA sequence (Watt et al., 1983) . These cDNAs were cloned into the transcription vector pBluescript KSII(+) (Stratagene, La Jolla, CA, USA) and used as templates for RNase protection assays.
Western blotting
Western blotting was performed with total cell lysates, nuclear lysates or cytosolic fractions from cultured cells or with lysates from normal and wounded skin (prepared as described by Werner et al., 1993) . Membranes were probed with a rabbit polyclonal antibody against Mad1 (sc-222, Santa Cruz Biotechnology, La Jolla, CA, USA) or with a monoclonal Mad1 antibody (Sommer et al., 1997) . Detection was performed with the enhanced chemoluminescence detection system (ECL; Amersham, Braunschweig, Germany).
Solid phase DNA-binding assay
Cells were lysed in F-buer (10 mM Tris/HCl pH 7.05, 50 mM NaCl, 31 mM sodium pyrophosphate, 5 mM ZnCl 2 , 1% Triton X-100, 1 mM PMSF, 0.15 U/ml aprotinin, 1% Leupeptin, 1% Pepstatin, and 1 mM Na 3 VO 4 ). The solid phase DNA-binding assay was performed as described by Larsson et al. (1997) . The oligonucleotides used were CMD (containing an optimal Myc/Max-binding site) and CMM (containing a mutated Myc/Max-binding site):
CMD: 5'-TCAGACCACGTGGTCGGG-3' CMM: 5'-TCAGACCAGCTGGTCGGG-3' We used a concentrated rabbit polyclonal antibody against Mad1 (sc-222 X, Santa Cruz Biotechnology, La Jolla, CA, USA).
Animals
BALB/c mice were obtained from RCC (FuÈ llinsdorf, Switzerland). They were housed and fed according to federal guidelines and all procedures were approved by the local authorities.
Wounding and preparation of wound tissue BALB/c mice (8 ± 12 weeks of age) were anaesthetized with a single intraperitoneal injection of ketamine/xylazine. The hair on the animals' back was shaved and the skin was wiped with 70% ethanol. Four full-thickness excisional wounds (5 mm diameter, 3 ± 4 mm apart) were generated on the back of each animal by excising skin and panniculus carnosus as described by Werner et al. (1994) . The wounds were allowed to dry to form a scab. Animals were sacri®ced at dierent time points after injury. For RNase protection assays the complete wounds including the epithelial margins were isolated at dierent time points after injury (12 h, 1, 3, 5, 7 and 13 or 14 days) and immediately frozen in liquid nitrogen until used for RNA isolation. Non-wounded back skin was used as a control. All protection assays were reproduced with RNAs from an independent wound healing experiment.
For in situ hybridization complete wounds were isolated at days 1 and 5 after injury, bisected, and ®xed overnight at 48C in 4% paraformaldehyde in PBS. They were subsequently incubated in 15% sucrose in PBS for 4 h at 48C and frozen in tissue freezing medium (Jung, Nussloch, Germany).
In situ hybridization
Sense and antisense riboprobes were generated using T3 or T7 RNA polymerases and [a-
35 S]UTP. Frozen sections (6 mm) from the middle of the wound or from normal and psoriatic human skin were hybridized as described by Wilkinson et al. (1987) . After hybridization, sections were coated with NTB2 nuclear emulsion (Kodak) and exposed in the dark for 3 ± 4 weeks. After development sections were counterstained with hematoxylin/eosin and mounted.
Human skin biopsies
Biopsies were obtained from stable psoriatic skin lesions located to the upper and lower extremities of psoriasis patients (n=8, age 33 ± 65 years). Normal skin was obtained from skin transplants of patients attending the Dermatology Department for surgery (n=5, aged 31 ± 79 years). All samples included the dermis and the epidermis. The biopsies were immediately frozen in liquid nitrogen and stored at 7808C until used for RNA isolation or ®xed in 4% paraformaldehyde and embedded in tissue freezing medium. None of the patients had received oral or topical treatment for the last 8 weeks before biopsy. All patients signed informed consent for the Department of Dermatology, University of Cologne, Germany, approved by the Institutional Commission of Ethics (Az. 9645/96).
